SEC Form 4 · accession 0000884731-16-000083
ARIAD PHARMACEUTICALS INC · ARIA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy P Clackson
Officer — President, R&D, CSO
Period of report
Jul 1, 2016
Accepted (ET)
Jul 5, 2016 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000884731
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 1, 2016 | M | 31,422 | $4.49 | A | 297,916 | D | |
| Common StockF3 | Jul 1, 2016 | S | 31,422 | $7.4837 | D | 266,494 | D | |
| Common Stock | Jul 1, 2016 | M | 30,000 | $3.25 | A | 296,494 | D | |
| Common StockF4 | Jul 1, 2016 | S | 30,000 | $7.4827 | D | 266,494 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy) | $4.49 | Jul 1, 2016 | M | 31,422 | D | Apr 16, 2008 | Apr 16, 2017 | Common Stock | 31,422 | 0 | D |
| Employee Stock Option (Right to Buy) | $3.25 | Jul 1, 2016 | M | 30,000 | D | Jun 25, 2011 | Jun 24, 2020 | Common Stock | 30,000 | 0 | D |
Explanation of responses
- F1Shares were acquired from exercise of an outstanding stock option pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2015
- F2Shares were sold pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2015
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.315 to $7.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer,or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.32 to $7.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer,or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.